An ionizable cationic BEND lipid
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

E10i-494

Item No. 43084

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
1,1'-((2-(2-(4-(2-((2-(2-(bis(2-hydroxy-13-methyltetradecyl)amino)ethoxy)ethyl)(2-hydroxy-13-methyltetradecyl)amino)ethyl)piperazin-1-yl)ethoxy)ethyl)azanediyl)bis(13-methyltetradecan-2-ol)
CAS Number
3031773-77-7
Molecular Formula
C89H183N5O7
Formula Weight
1435.5
Purity
≥95% (mixture of isomers)
Formulation (Request formulation change)
A 10 mg/ml solution in ethanol
Solubility(Learn about Variance in Solubility)
Ethanol: Soluble: ≥ 10 mg/ml
SMILES
OC(CCCCCCCCCCC(C)C)CN(CCOCCN(CCN(CC1)CCN1CCOCCN(CC(CCCCCCCCCCC(C)C)O)CC(CCCCCCCCCCC(C)C)O)CC(O)CCCCCCCCCCC(C)C)CC(O)CCCCCCCCCCC(C)C
InChi Code
InChI=1S/C89H183N5O7/c1-80(2)51-41-31-21-11-16-26-36-46-56-85(95)75-92(68-72-101-74-70-94(78-88(98)59-49-39-29-19-14-24-34-44-54-83(7)8)79-89(99)60-50-40-30-20-15-25-35-45-55-84(9)10)66-65-90-61-63-91(64-62-90)67-71-100-73-69-93(76-86(96)57-47-37-27-17-12-22-32-42-52-81(3)4)77-87(97)58-48-38-28-18-13-23-33-43-53-82(5)6/h80-89,95-99H,11-79H2,1-10H3
InChi Key
QKCHHRREJZYEPH-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $84

    Add

    5 mg

    $314

    Add

    10 mg

    $460

    Add
    Cayman Chemical
    Ionizable Lipids – Your Path from R&D to GMP

    Seamlessly bridge your LNP discovery journey from RUO to bulk GLP-tox and GMP excipient-grade material.

    Explore CGMP Lipid Services
    Product Description

    E10i-494 is an ionizable cationic branched endosomal disruptor (BEND) lipid that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA and small molecules in vitro and in vivo.1,2 LNPs containing E10i-494 and encapsulating mCherry or luciferase mRNA induce mCherry or luciferase expression in T cells.1 LNPs containing E10i-494 and encapsulating p53 mRNA, ciclopirox (CPX; Item No. 16021), or both p53 mRNA and CPX alter the tumor immune microenvironment (TIME) by repolarizing tumor-associated macrophage (TAM)-like cells generated in vitro under conditions mimicking the oral squamous cell carcinoma microenvironment to an M1-like phenotype.2 E10i-494-containing LNPs encapsulating p53 mRNA, CPX, or both p53 mRNA and CPX reduce tumor volume and mass in a CAL 27 tongue squamous cell carcinoma mouse xenograft model.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Padilla, M.S., Mrksich, K., Wang, Y., et al. Branched endosomal disruptor (BEND) lipids mediate delivery of mRNA and CRISPR-Cas9 ribonucleoprotein complex for hepatic gene editing and T cell engineering. Nat. Commun. 16(1), 996 (2025).

    2. Padilla, M.S., Li, J.J., Zhang, Q., et al. Lipid nanoparticle co-delivery of mRNA and a small molecule drug for oral cancer chemoimmunotherapy. bioRxiv [Preprint] (2025).